Efficacy and Safety With Ziprasidone in First-episode Psychosis

2010-07-15 17:00:00 | BioPortfolio


The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


First Episode Psychosis




Department of Psychiatry, Chonbuk national University Hospital
Korea, Republic of




Chonbuk National University Hospital

Results (where available)

View Results


Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [356 Associated Clinical Trials listed on BioPortfolio]

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

The purpose of this study is to evaluate the efficacy and tolerability of ziprasidone in patients who successfully completed a study of ziprasidone treatment of psychosis (Protocol A128107...

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment ...

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, ...

Ziprasidone in the Psychosis Prodrome

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Role of Minocycline in First Episode Psychosis

The purpose of this study is to determine whether the addition of minocycline or placebo to treatment as usual (TAU): 1. prevents the accumulation of negative symptoms and intellectual ...

PubMed Articles [606 Associated PubMed Articles listed on BioPortfolio]

Depression and functioning are important to subjective quality of life after a first episode psychosis.

Subjective quality of life (S-QoL) is an important outcome measure in first-episode psychosis, but its associations with clinical predictors may vary across the illness course. In this study we examin...

Early interventions in a US military FIRST episode psychosis program.

Naval Medical Center San Diego's Psychiatric Transition Program is a specialized first episode psychosis treatment program that delivers coordinated specialty care to military service members with psy...

First episode psychosis and comorbid ADHD, autism and intellectual disability.

Comorbidity between neurodevelopmental disorders and psychotic disorders is common, but little is known about how neurodevelopmental disorders influence the presentation and outcome of first episode p...

Prosody abilities in a large sample of affective and non-affective first episode psychosis patients.

Prosody comprehension deficits have been reported in major psychoses. It is still not clear whether these deficits occur at early psychosis stages. The aims of our study were to investigate a) linguis...

Adherence to Follow-Up in First-Episode Psychosis: Ethnicity Factors and Case Manager Perceptions.

To determine whether visible minority patients with first-episode psychosis are at higher risk for treatment nonadherence than white patients and elicit the perceptions of case managers regarding visi...

Medical and Biotech [MESH] Definitions

An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode but that does not usually result in MYOCARDIAL INFARCTION.

Reactions to an event or set of events which are considered to be of pathological degree, that have not developed into a neurosis, psychosis, or personality disorder with fixed patterns.

A highly toxic compound used as a gasoline additive. It causes acute toxic psychosis or chronic poisoning if inhaled or absorbed through the skin.

One of the FLAVORING AGENTS used to impart a meat-like flavor. Medically it has been used to reduce blood ammonia levels in ammoniacal azotemia, therapy of hepatic coma, in psychosis, and mental retardation.

Capacity that enables an individual to cope with and/or recover from the impact of a neural injury or a psychotic episode.

More From BioPortfolio on "Efficacy and Safety With Ziprasidone in First-episode Psychosis"

Quick Search


Searches Linking to this Trial